Cormorant Asset Management, LP Moon Lake Immunotherapeutics Transaction History
Cormorant Asset Management, LP
- $1.74 Billion
- Q1 2024
A detailed history of Cormorant Asset Management, LP transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Cormorant Asset Management, LP holds 8,494,151 shares of MLTX stock, worth $345 Million. This represents 24.56% of its overall portfolio holdings.
Number of Shares
8,494,151
Previous 8,494,151
-0.0%
Holding current value
$345 Million
Previous $513 Million
16.82%
% of portfolio
24.56%
Previous 30.89%
Shares
4 transactions
Others Institutions Holding MLTX
# of Institutions
135Shares Held
56MCall Options Held
379KPut Options Held
402K-
Bvf Inc San Francisco, CA21.8MShares$884 Million32.73% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.58MShares$105 Million1.56% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.31MShares$93.9 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.28MShares$92.9 Million0.23% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.14MShares$86.8 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.5B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...